Tag: safety profile

HONG KONG, Oct. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a...

Phase 3 data presented at Fall Clinical Dermatology show high, sustained response rates in adults and adolescents, with nearly three-quarters achieving clear or almost...

In a head-to-head Phase 3 trial, prifemilast nearly doubled the rate of PASI 75 response compared with apremilast and achieved superiority on both co-primary...

SYCUME® Significantly Improved Proptosis (Response Rate 60.4% / LS Mean Change from Baseline -1.88 mm) with Favorable Safety Profile in Participants with Inactive Thyroid...

LONDON, Oct. 8, 2026 /PRNewswire/ -- Curaleaf International has announced the launch of the Curaleaf Education Platform in Poland, giving healthcare professionals across the...

Approximately 110 participants enrolled in randomized, double-blind, placebo-controlled study; topline results expected in the second quarter of 2027MIAMI, Oct. 7, 2026 /PRNewswire/ -- Resolve...

Results from an 18-week, open-label Phase Ib trial of investigational Lu AF28996 in people with advanced Parkinson's disease are being presented at MDS 2026The...

The new CSL Seqirus-developed vaccine will be introduced to the annual influenza vaccination programme from next year (2027/28).Its introduction marks a significant advance in...

TYLENOL® with Naproxen is a clinically proven, opioid-free, fixed-dose combination that begins working in under 30 minutes and provides 12 hours of pain relief...

PALMA DE MALLORCA, Spain, July 23, 2026 /PRNewswire/ -- Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid...

PALMA DE MALLORCA, Spain, July 23, 2026 /CNW/ -- Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid...

SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval includes a...

WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that new analyses from the Phase 3 FoCus randomized controlled clinical trial of ALXN1840 (tiomolibdate choline, TMC) will be presented at the 12th Congress of the European Academy of Neurology (EAN 2026), June 27–30, 2026, in Geneva, Switzerland. These analyses build upon the previously reported Phase 3 FoCus results demonstrating ALXN1840 met its primary endpoint of superior copper mobilization versus standard of care.